Radiolabeled Affibody Imaging for HER2 Status Assessment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for accurately assessing HER2 status in cancer patients are invasive, prone to errors due to spatial heterogeneity, and can lead to unnecessary toxicity or withdrawal from therapy, especially in cases where locoregional and distant recurrences are not amenable to biopsy.

Innovation Solution

The use of a HER2-targeting Affibody molecule, [18F]GE-226, which is a radiolabeled polypeptide that binds specifically to HER2, allowing for non-invasive imaging and monitoring of HER2 expression and response to HSP90 inhibition through PET imaging.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If invasive biopsy methods are used to assess HER2 status, then measurement precision is improved, but ease of operation deteriorates and object-affected harmful factors increase

Engineering Contradiction:

ImproveHER2 status assessment accuracyVSAvoidPatient accessibility to testing

Core Design Contradiction:

Measurement precisionVSEase of operation

Solution Approach 1:

The patent replaces invasive mechanical biopsy procedures with non-invasive molecular imaging techniques. Radiolabeled Affibody molecules are administered systemically and accumulate at tumor sites, allowing HER2 status assessment through external imaging rather than surgical tissue sampling. This substitution eliminates procedural invasiveness while maintaining diagnostic capability.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces radiolabeled Affibody molecules as intermediary agents that mediate between the diagnostic system and the target HER2 receptors. These molecules specifically bind to HER2-expressing tumors, carrying radioactive labels that can be detected externally. This intermediary approach enables indirect observation of HER2 status without direct tissue intervention.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Measurement precision

If biopsy-based HER2 testing is performed, then measurement precision is improved, but loss of time increases due to procedural complexity

Engineering Contradiction:

ImproveHER2 status determination accuracyVSAvoidTime from patient presentation to therapy decision

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent performs preliminary diagnostic action through molecular imaging that can be integrated into the treatment workflow. The radiolabeled Affibody molecules provide rapid HER2 status determination that informs subsequent therapy decisions, enabling proactive patient management rather than reactive delays for separate biopsy procedures.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent merges diagnostic and therapeutic planning functions into a single integrated process. The molecular imaging procedure simultaneously provides anatomical localization, functional assessment, and molecular characterization (HER2 status), consolidating multiple diagnostic steps that would otherwise require separate invasive procedures and extended timeframes.

Inventive Principle:

Principle #5Merging (Combining)

3Ease of operation

If current imaging methods are used, then non-invasive detection is achieved, but measurement precision deteriorates due to prolonged tracer retention in liver and kidneys

Engineering Contradiction:

ImproveNon-invasive imaging capabilityVSAvoidMetastasis detection accuracy

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent employs short-lived radioisotopes (such as 68Ga with half-life of approximately 68 minutes or 18F with half-life of approximately 110 minutes) that decay rapidly after imaging. This allows high-quality images to be obtained quickly before significant radioactive decay occurs, minimizing prolonged tracer retention issues while maintaining diagnostic precision for metastasis detection.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

[18F]GE-226 provides a viable strategy for determining differential HER2 expression within one hour of injection, independent of cell lineage or prior trastuzumab treatment, enabling accurate monitoring of HER2 status and predicting response to HSP90 inhibition, thereby improving patient stratification and reducing toxicity risks.

Implementation Method 1

Tumor marker-targeted molecular imaging using radiolabeled Affibody molecules

Methodology Applied

Scientific EffectRadioactive decay: Radioactive Decay

Implementation Method 2

the isolated polypeptide binds specifically to HER2

Methodology Applied

Scientific EffectSpecific binding:

Data Source

PatentUS10646600B2HER2 polypeptides useful for imaging and monitoring tumors and cancers

Publication Date: 2020.05.12 GE HEALTHCARE LTD

AI summary

A method of use of an isolated polypeptide conjugated with a radionuclide, wherein the isolated polypeptide binds specifically to HER2, or a variant thereof is described. The method is for monitoring the response to HSP90 inhibition and comprises the use of the isolated polypeptide conjugated with 18F. The application also describes the use of an isolated polypeptide conjugated with 18F, wherein the isolated polypeptide binds specifically to HER2 or variants thereof, as an imaging agent to monitor uptake thereof to measure HSP90 inhibition.